CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	423.31	347.56	298.26	389.48	211.89	923.03
Short-Term Investments	2,018	1,628	1,606	1,304	1,603	1,456
Cash & Short-Term Investments	2,442	1,976	1,904	1,694	1,815	2,379
Cash Growth	31.61%	3.78%	12.41%	-6.70%	-23.70%	40.75%
Accounts Receivable	-	-	25	200	-	0.31
Other Current Assets	6.58	9.84	8.31	14.39	37.71	38.08
Total Current Assets	2,448	1,986	1,937	1,908	1,853	2,418
Net Property, Plant & Equipment	240.85	247.58	277.55	305.94	320.56	312.04
Other Intangible Assets	-	-	-	0.02	0.07	0.13
Long-Term Investments	-	-	-	1.97	53.13	-
Other Long-Term Assets	36.61	32	27.35	13.57	16.28	22.2
Total Assets	2,726	2,265	2,242	2,230	2,243	2,752
Accounts Payable	13.65	11.14	14.71	38.15	27.43	14.82
Accrued Expenses	75.57	90.52	41.52	45.77	77.82	91.73
Current Portion of Leases	18.61	18.58	17.29	15.63	15.84	12.16
Unearned Revenue	15.34	15.77	3.85	4.11	-	1.01
Other Current Liabilities	13.11	13.11	10.42	5.14	0.02	0.17
Total Current Liabilities	136.29	149.12	87.78	108.79	121.11	119.88
Long-Term Debt	585.47	-	-	-	-	-
Long-Term Leases	183.56	188.17	206.41	223.01	228.18	212.87
Other Long-Term Liabilities	5.95	6.14	15.77	14.97	18.29	19.66
Total Long-Term Liabilities	774.98	194.31	222.17	237.98	246.47	232.53
Total Liabilities	911.26	343.43	309.95	346.77	367.58	352.42
Common Stock	3.12	3.09	2.7	2.5	2.44	2.39
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Additional Paid-in Capital	3,884	3,862	3,294	2,878	2,735	2,598
Accumulated Other Comprehensive Income	-1.94	4.82	1.84	1.91	-15.65	-5.07
Retained Earnings	-2,070	-1,948	-1,366	-999.7	-846.09	-195.92
Shareholders' Equity	1,815	1,922	1,932	1,883	1,875	2,399
Total Liabilities & Equity	2,726	2,265	2,242	2,230	2,243	2,752
Total Debt	787.64	206.75	223.69	238.63	244.02	225.03
Net Cash (Debt)	1,654	1,769	1,680	1,455	1,571	2,154
Net Cash Growth	-6.50%	5.29%	15.47%	-7.40%	-27.05%	32.24%
Net Cash Per Share	17.90	19.67	19.92	18.37	20.21	26.79
Book Value	1,815	1,922	1,932	1,883	1,875	2,399
Book Value Per Share	19.63	21.37	22.90	23.77	24.12	29.85
Tangible Book Value	1,815	1,922	1,932	1,883	1,875	2,399
Tangible Book Value Per Share	19.63	21.37	22.90	23.77	24.12	29.84

SEC Filings: 10-K · 10-Q